Pharmacological synergistic multi-target of Curcuma longa compounds to minimise the ototoxic effects and resistance of cisplatin in ovarian cancer treatment: integration of bibliometric analysis, pharmacological networking, and molecular docking approaches.

This study explores the pharmacological synergy between Curcuma longa (turmeric) compounds and cisplatin in ovarian cancer treatment, focusing on overcoming drug resistance and minimizing toxicity. Using bibliometric analysis with tools like Publish or Perish and VOSviewer, the research identifies significant novelty in this field. Active compounds of C. longa were screened for drug-likeness and oral bioavailability through Molsoft and SwissADME, while potential therapeutic targets were predicted using databases such as SwissTargetPrediction, GeneCards, and DrugBank. Network pharmacology and PPI analysis via Cytoscape and STRING, along with GO and REACTOME enrichment via DAVID. In the pharmacological network, quercetin, cytosolic tRNA aminoacylation, and ALOX5 (arachidonate 5-lipoxygenase) are the substances, targets, and pathways with the highest degrees. The PPI target with the highest degree is TP53 (tumor protein p53). GO enrichment (BP, CC, MF) and REACTOME are cytosolic tRNA aminoacylation, tRNA aminoacylation, and mucopolysaccharidoses. Docking simulations showed strong binding between campesterol and CDK2 (-10.8 kcal/mol) as well as campesterol and TP53 (-9.7 kcal/mol). These results suggest that C. longa compounds could enhance cisplatin's anticancer activity, reduce toxicity, and help overcome drug resistance in ovarian cancer therapy. The findings highlight the potential for natural, polyphenol-rich agents to complement chemotherapy and improve treatment outcomes.